# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.
- Bloomberg
Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesity ...
HC Wainwright & Co. analyst Douglas Tsao reiterates Evotec (NASDAQ:EVO) with a Buy and maintains $11 price target.